Compare JEF & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JEF | PODD |
|---|---|---|
| Founded | 1968 | 2000 |
| Country | United States | United States |
| Employees | N/A | 5400 |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 10.2B |
| IPO Year | 2016 | 2007 |
| Metric | JEF | PODD |
|---|---|---|
| Price | $55.23 | $147.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | $61.40 | ★ $341.48 |
| AVG Volume (30 Days) | 1.6M | ★ 1.6M |
| Earning Date | 03-25-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.70 | ★ 2.67 |
| Revenue | ★ $10,823,677,000.00 | $2,708,100,000.00 |
| Revenue This Year | $13.23 | $24.55 |
| Revenue Next Year | $10.25 | $19.18 |
| P/E Ratio | $76.78 | ★ $56.08 |
| Revenue Growth | 2.93 | ★ 30.73 |
| 52 Week Low | $35.53 | $126.40 |
| 52 Week High | $71.04 | $354.88 |
| Indicator | JEF | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 50.87 |
| Support Level | $51.10 | $139.67 |
| Resistance Level | $54.53 | $155.17 |
| Average True Range (ATR) | 1.43 | 5.28 |
| MACD | 0.02 | 0.94 |
| Stochastic Oscillator | 62.10 | 67.83 |
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.